在检测阿尔茨海默氏病时,大脑意识替代监督对比学习
Mehmet Saygın Seyfioğlu1, Zixuan Liu1, Pranav Kamath1
1University of Washington, Seattle, WA 98195, USA.
Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention
|April 29, 2024
概括
这项研究引入了使用脑MRI检测阿尔茨海默病 (AD) 的新框架. 这种新的方法增强了合成MRI数据,并使用了专门的损失函数,提高了检测准确性.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 的诊断严重依赖于神经成像,特别是MRI.
- 准确和早期发现AD对于有效的患者管理至关重要.
- 现有的数据增强技术可能无法完全捕捉大脑MRI数据的复杂性.
研究的目的:
- 开发一种新的框架,用于使用脑MRI检测阿尔茨海默病 (AD).
- 引入一种新的数据增强方法,脑意识替代 (BAR),用于生成现实的合成脑MRI.
- 为了提高AD检测模型的精度和回忆.
主要方法:
- 提出了一种数据增强技术 (大脑意识替代 - BAR),使用大脑分片来创建合成MRI.
- 实施了一种能够进行软标签的监督对比损失功能.
- 使用提出的框架预训练模型,并通过交叉损失进行微调.
- 将框架与从头开始监督培训和最先进的自我监督方法进行了比较.
主要成果:
- 该BAR方法产生了现实的合成MRI,其局部变异性高于CutMix.
- 拟议的框架实现了对阿尔茨海默病检测的卓越精度和回忆.
- 预先训练的模型在用硬标签微调时表现出有效性.
结论:
- 这种新的框架显著提高了阿尔茨海默病检测性能.
- 脑意识替代 (BAR) 是用于医学成像的有效数据增强技术.
- 拟议的方法为改善神经退行性疾病的诊断准确性提供了一个有希望的方向.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:24Prosopagnosia
159
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
159